Articles published in Pulmonary & Respiratory Medicine have been cited by esteemed scholars and scientists all around the world.
Pulmonary & Respiratory Medicine has got h-index 20, which means every article in Pulmonary & Respiratory Medicine has got 20 average citations.
Following are the list of articles that have cited the articles published in Pulmonary & Respiratory Medicine.
2024 | 2023 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|
Total published articles |
40 | 49 | 60 | 28 | 19 | 41 |
Research, Review articles and Editorials |
3 | 1 | 0 | 0 | 0 | 0 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
37 | 48 | 0 | 0 | 0 | 0 |
Conference proceedings |
0 | 0 | 16 | 0 | 11 | 57 |
Citations received as per Google Scholar, other indexing platforms and portals |
1784 | 1347 | 168 | 194 | 193 | 169 |
Journal total citations count | 1690 |
Journal impact factor | 1.80 |
Journal 5 years impact factor | 2.06 |
Journal cite score | 6.21 |
Journal h-index | 20 |
Journal h-index since 2019 | 15 |
Matera MG, Ora J, Cazzola M (2015) Differential pharmacology and clinical utility of long-acting bronchodilators in COPD–focus on olodaterol. Therapeutics and clinical risk management 11: 1805. |
|
Melani AS (2015) Long-acting muscarinic antagonists. Expert review of clinical pharmacology 8: 479-501. |
|
Joos GF, Aumann JL, Coeck C, Korducki L, Hamilton AL, et al. (2015) A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV 1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β 2-agonist, in patients with chronic obstructive pulmonary disease. Respiratory medicine. 109: 606-615. |
|
Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, et al. (2015) Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat® Inhaler in patients with chronic obstructive pulmonary disease. Advances in therapy. 32: 809-822. |
|
Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, et al. (2015) A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β 2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respiratory medicine. 109: 596-605. |
|
Deeks ED (2015) Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75: 665-673. |
|
Disse B, Becker K (2014) Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. International Journal of COPD 9: 813-824. |
|
Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, et al. (2015) The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulmonary pharmacology & therapeutics. 32: 53-59. |
|
Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, et al. (2015) Tiotropium+ olodaterol shows clinically meaningful improvements in quality of life. Respiratory medicine. 109: 1312-1329. |
|
Zamora-Chávez A, Sadowinski-Pine S, Serrano-Bello C, Velázquez-Jones L, Saucedo-Ramírez OJ, et al. (2016) Sarcoidosis en la infancia. Una rara enfermedad sistémica. Boletín Médico del Hospital Infantil de México. 73: 117-128. |
|
Raspanti GA. LUNG CANCER IN NEPAL: THE ROLE OF TRADITIONAL TOBACCO PRODUCTS AND COMBUSTION RELATED HOUSEHOLD AIR POLLUTION (Doctoral dissertation). |
|
KuršvietienÄ— L, StaneviÄÂienÄ— I. AKTYVIŲJŲ DEGUONIES FORMŲ IR ANTIOKSIDANTŲ POVEIKIS BIOMOLEKULÄ–MS IR REIKŠMÄ– LIGŲ PATOGENEZÄ–JE. Redaktorių taryba.:9. |
|
Janssen WJ, Nozik-Grayck E. Power of Place: Intravascular Superoxide Dismutase for Prevention of Acute Respiratory Distress Syndrome. |
|
Lunguleac T, Balmus IM, Grigorescu C. OXIDATIVE STRESS IMPLICATIONS IN VARIOUS LUNG DISEASES. FOCUSING ON ONE LUNG VENTILATION. |
|
Applying biotechnology and bioengineering to pediatric lung disease: emerging paradigms and platforms |
|
Dingemanse J, Bolli M, Iglarz M (2015) Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1. Expert opinion on therapeutic patents 25: 1069-1077. |
|
Feher A, Sinusas AJ. Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension. |
|
Kim HJ, Yoo HY (2016) Hypoxic pulmonary vasoconstriction and vascular contractility in monocrotaline-induced pulmonary arterial hypertensive rats. The Korean Journal of Physiology & Pharmacology 20: 641-647. |
|
Karch SB, Vaiano F, Bertol E (2015) Levamisole, Aminorex, and Pulmonary Arterial Hypertension: A Review. Razavi International Journal of Medicine: 3. |
|
BellÃ?Æ?Ã?³-Klein A, Araujo AS, Schenkel PC, de Lima Seolin BG (2016) Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. InBiochemistry of Oxidative Stress. Springer International Publishing: 213-226. |
|
Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report